Critical Issues in Chronic Illnesses of Women

  • LeAdelle PhelpsEmail author
Part of the Issues of Diversity in Clinical Neuropsychology book series (ISSUESDIV)

It is well known that gender is one of the most important determinants of physical health. This is for several reasons. First, the sex chromosomes (X, Y) may malfunction, causing a multitude of problems. For example, some disorders occur almost exclusively in males because of a faulty gene carried on the X chromosome (e.g., hemophilia, Lesch–Nyhan, Lowe syndrome). In order for a female to be affected by X-linked illnesses, she must inherit the faulty gene from both parents, which rarely happens. Likewise, some anomalies occur because of the complete absence (e.g., Turner syndrome, genetic designation XO) or extra copies of the X chromosome (Klinefelter syndrome, XXY, or XXXY).

Second, some disorders occur far more commonly in one gender than the other, but these syndromes are not related directly to the X or Y chromosome. For example, externalizing disorders such as attention-deficit/hyperactivity disorder (ADHD), oppositional defiant disorder, and conduct disorder are far more...


Multiple Sclerosis Cognitive Behavioral Therapy Turner Syndrome Oppositional Defiant Disorder Heavy Menstrual Bleeding 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Ablin, J. N., Cohen, H., & Buskila, D. (2006). Mechanisms of disease: genetics of fibromyalgia. Rheumatology, 2, 671–678.PubMedGoogle Scholar
  2. Anderberg, U. M., Marteinsdottir, I., & Knorring, L. von. (2000). Citalopram in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. European Journal of Pain, 4, 27–35.PubMedCrossRefGoogle Scholar
  3. Arnold, L. M., Hudson, J. I., Hess, E. V., Wure, A. E., Fritz, D. A., Auchenback, M. B., et al. (2004). Family study of fibromyalgia. Arthritis and Rheumatism, 50, 944–952.PubMedCrossRefGoogle Scholar
  4. Arnold, L. M., Keck, P. E., & Welge, J. A. (2000). Antidepressant treatment of fibromyalgia: a meta-analysis and review. Psychosomatics, 41, 104–113.PubMedCrossRefGoogle Scholar
  5. Baranzini, S. E., & Oksenberg, J. R. (2005). Genomics and new targets for multiple sclerosis. Pharmacogenomics, 6, 151–161.PubMedCrossRefGoogle Scholar
  6. Chofflon, M. (2005). Mechanisms of action for treatments in multiple sclerosis. BioDrugs, 19, 299–308.PubMedCrossRefGoogle Scholar
  7. Cohen, H., Hagit, B., Neumann, J., & Ebstein, R. P. (2002). Confirmation of an association of fibromyalgia and serotonin transporter promoter region polymorphism, and relationship to anxiety related personality traits. Arthritis and Rheumatism, 46, 645–847.Google Scholar
  8. Confavreux, C., Hutchinson, M., Hours, M., Hours, M. M., Cortinovis-Tourniaire, P., & Moreau, T. (1998). Rate of pregnancy-related relapse in multiple sclerosis. New England Journal of Medicine, 339, 285–289.PubMedCrossRefGoogle Scholar
  9. Coyle, P., Christie, S., Fodor, P., Fuchs, K., Glesser, B., Gutierrez, A., et al. (2004). Multiple sclerosis gender issues: clinical practices of women neurologists. Multiple Sclerosis, 10, 582–588.PubMedCrossRefGoogle Scholar
  10. Crofford, L. J., Russell, J., & Mease, P. (2002). Pregabalin improves pain associated with fibromyalgia syndrome in a multicenter, randomized, placebo-controlled monotherapy trial. Arthritis and Rheumatism, 46, suppl. S613.Google Scholar
  11. Davis, S. N., Galassetti, P., Waserman, D. H., & Tate, D. (2000). Effects of gender on neuroendocrine and metabolic counter regulatory responses to exercise in normal men. Journal of Clinical Endocrinology and Metabolism, 85, 224–230.PubMedCrossRefGoogle Scholar
  12. Dessein, P. H., Shipton, E. A., & Stanwix, A. E. (2000). Neuroendocrine deficiency-mediated development and persistence of pain in fibromyalgia: a promising paradigm? Pain, 86, 213–215.PubMedCrossRefGoogle Scholar
  13. El-Etr, M., Vukusic, S., Gignoux, L., Durand-Dubiet, F., Achiti, I., Baulieu, E. E., et al. (2005). Steroid hormones in multiple sclerosis. Journal of the Neurological Sciences, 233 49–54.PubMedCrossRefGoogle Scholar
  14. Ferrero, S., Pretta, S., & Regani, N. (2004). Multiple sclerosis: management issues during pregnancy. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 115, 3–9.PubMedCrossRefGoogle Scholar
  15. Frank, B., Niesler, B., Bondy, B., Spath, M., Pongratz, D. E., Achenheil, M., et al. (2004). Mutational analysis of serotonin receptor genes HTR3A and HTR3B in fibromyalgia patients. Clinical Rheumatology, 23, 338–344.PubMedCrossRefGoogle Scholar
  16. Friedberg, F., & Jason, L. A. (2001). Chronic fatigue syndrome fibromyalgia: Clinical assessment and treatment. Journal of Clinical Psychology, 57, 433–455.Google Scholar
  17. Gandhi, N., DePauw, K. P., Dolny, D. G., & Freson, T. (2002). Effect of an exercise program on quality of life of women with fibromyalgia. Women and Therapy, 25, 91–103.CrossRefGoogle Scholar
  18. Goldenberg, D. L., Burckhardt, C., & Crofford, L. (2004). Management of fibromyalgia syndrome.Journal of the American Medical Association, 292, 2388–2395.PubMedCrossRefGoogle Scholar
  19. International Multiple Sclerosis Genetics Consortium. (2008). Risk alleles for MS identified by a genomewide study. New England Journal of Medicine, 357, 851–862.Google Scholar
  20. Kajantie, E., & Phillips, D. W. (2006). The effects of sex and hormonal status on the physiological response to acute psychosocial stress. Psychoneuroendocrinology, 31, 151–178.PubMedCrossRefGoogle Scholar
  21. Kirschbaum, C., Kudielka, B. M., Gaab, J., Schommer, N. C., & Hellhammer, D. H. (1999). Impact of gender, menstrual cycle phase, and oral contraceptives on the activity of the hypothalamus-pituitary-adrenal axis. Psychosomatic Medicine, 61, 154–162.PubMedGoogle Scholar
  22. Koch, S., Goedde, R., Nigmatov, V., Epplen, J. T., Muller, N., Seze, J. de, et al. (2005). Association of multiple sclerosis with ILT6 deficiency. Genes and Immunity, 6, 445–447.PubMedCrossRefGoogle Scholar
  23. Koenig, H., Schumacher, M., Ferazz, B., Thi, A. N., Ressouches, A., Guemoun, R., et al. (1995). Progesterone synthesis and myelin formation by Schwann cells. Science, 268, 1500–1503.PubMedCrossRefGoogle Scholar
  24. Mastorakos, G., & Ilias, L. (2003). Maternal and fetal hypothalamic-pituitary-adrenal axes during pregnancy and postpartum. Annals of New York Academy of Sciences, 997, 136–149.CrossRefGoogle Scholar
  25. Mease, P. (2005). Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. Journal of Rheumatology, 32, 621.Google Scholar
  26. Offenbaecher, M., Bondy, B., deJonge, S., Glatzeder, K., Kruger, M., Schoeps, P., et al. (1999). Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis and Rheumatism, 42, 2482–2488.PubMedCrossRefGoogle Scholar
  27. Oksenberg, J. R., Baranzini, S. E., Barcellos, L. F., & Hauser, S. L. (2001). Multiple sclerosis: genomic rewards. Journal of Neuroimmunology, 113, 171–184.PubMedCrossRefGoogle Scholar
  28. Oksenberg, J. R., & Barcellos, L. F. (2005). Multiple sclerosis: leaving no stone unturned. Genes and Immunity, 6, 375–387.PubMedCrossRefGoogle Scholar
  29. Orton, S., Herrera, B., Valdar, W., Ramagoplan, S. V., Sadovnick, A. D., & Ebers, G. C. (2006). Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet, 5, 932–936.CrossRefGoogle Scholar
  30. Otte, C., Hart, S., Neylan, T. C., Marmar, C. R., Yaffe, K., & Mohr, D. C. (2005). A meta-analysis of cortisol response to challenge in human aging: importance of gender. Psychoneuroendocrinology, 30, 80–91.PubMedCrossRefGoogle Scholar
  31. Pohl, D., Krone, B., & Rostasy, K. (2006). High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology, 67, 2063–2065.PubMedCrossRefGoogle Scholar
  32. Pozzili, C., Falaschi, P., Mainero, C., Martocchia, A., D’Urso, R., & Poroietti, A. (1999). MRI in multiple sclerosis during the menstrual cycle: relationship with sex hormone patterns. Neurology, 53, 622–624.Google Scholar
  33. Ransohoff, R. M. (2007). Natalizumab for multiple sclerosis. New England Journal of Medicine, 356, 2622–2629.PubMedCrossRefGoogle Scholar
  34. Richards, S. C., & Scott, D. L. (2002). Prescribed exercise in people with fibromyalgia: parallel group randomized control trail. British Medical Journal, 325, 185.PubMedCrossRefGoogle Scholar
  35. Rossy, L. A., Bickelew, S. P., Dorr, N., Hagglund, K. J., Thayer, J. F., McIntosh, M. J., et al. (1999). A meta-analysis of fibromyalgia treatment interventions. Annals of Behavioral Medicine, 21, 180–191.PubMedCrossRefGoogle Scholar
  36. Russler, K. J., & Nemeroff, C. B. (2000). Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depression and Anxiety, 12, 2–19.CrossRefGoogle Scholar
  37. Sandberg-Wollheim, M., Frank, D., Goodwin, T. M., Gisser, B., Lopez-Bresnahan, M., Stam-Moraga, M., et al. (2005). Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology, 65, 802–806.PubMedCrossRefGoogle Scholar
  38. Sarzi-Puttini, P., Atzeni, F., Diana, A., Doria, A., & Furlan, R. (2006). Increased neural sympathetic activation in fibromyalgia syndrome. Annals of New York Academy of Sciences, 1069, 109–117.CrossRefGoogle Scholar
  39. Shaver, J. L. (2004). Fibromyalgia in women. Nursing Clinics of North America, 39, 195–204.PubMedCrossRefGoogle Scholar
  40. Sicotte, N., Liva, S., Klutch, R., Pfeiffer, P., Odesa, W., Wu, T. C., et al. (2002). Treatment of multiple sclerosis with the pregnancy hormone estriol. Annals of Neurology, 52, 421–428.PubMedCrossRefGoogle Scholar
  41. Stuart, W. H., & Varmersch, P. (2004). Concomitant therapy for multiple Sclerosis. Neurology, 63, 528–534.Google Scholar
  42. Transatlantic Multiple Sclerosis Genetics Cooperative. (2003). A meta-analysis of whole genome linkage screens in multiple sclerosis. Journal of Neuroimmunology, 143, 39–46.CrossRefGoogle Scholar
  43. Tsigos, C., & Chrousos, G. P. (2002). Hypothalamic-pituitary-adrenal axis, neuro-endocrine functions and stress. Journal of Psychosomatic Research, 53 865–871.PubMedCrossRefGoogle Scholar
  44. Vukusic, S., & Confavreux, C. (2006). Pregnancy and multiple sclerosis: the children of PRIMS. Clinical Neurology and Neurosurgery, 108 206–270.CrossRefGoogle Scholar
  45. Vukusic, S., Hutchinson, M., Hours, M., Moreau, T., Cortinovie-Tourniaire, P., Adeleine, P., & Confavreux, C. (2004). Pregnancy and the PRIMS study: clinical predictors of post-partum relapse. Brain, 127 1353–1369.PubMedCrossRefGoogle Scholar
  46. Wolfe, F., Anderson, J., Harkness, D., Bennett, R. M., Caro, X. J., Goldenberg, D. L., et al. (1997). Health status and disease severity in fibromyalgia: results of a six-center longitudinal study. Arthritis and Rheumatism, 40 1571–1579.PubMedCrossRefGoogle Scholar
  47. Zhu, W., Lu, C., Huang, Y., Link, H., & Xiao, B. (2007). A putative mechanism on remission of multiple sclerosis during pregnancy: estrogen-induced indoleamine, 2,3 dioxgenase by dendritic cells. Multiple Sclerosis, 13 33–40.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.University at BuffaloSUNY

Personalised recommendations